Plasma neurofilament light chain predicts progression in progressive supranuclear palsy

Abstract

Plasma NfL is elevated in PSP and could be of value as a biomarker both to assist clinical diagnosis and to monitor pharmacodynamic effects on the neurodegenerative process in clinical trials.